无创心脏影像学与临床前A/B期受试者心力衰竭进展的预测
综述指出,收缩、舒张及结构左心室参数均可预测症状性心衰,但单一参数灵敏度不足;经胸超声心动图可同时测量这三类参数,在≥65岁A/B期人群中至少检出1项异常者占>50%,且该异常对后续发生症状性心衰的灵敏度为72%~82%;作者认为可对≥65岁社区A/B期人群用经胸超声心动图筛查以识别高风险者并给予预防治疗,年轻人群的最佳策略需进一步研究。
要点
- 收缩、舒张及结构左心室参数各自预测症状性心衰,但无单一参数灵敏度足以筛查A/B期进展风险。
- 经胸超声心动图可同时评估收缩、舒张及结构参数,在≥65岁A/B期人群中>50%至少检出1项异常。
- ≥65岁A/B期人群经胸超声心动图至少1项异常预测后续症状性心衰的灵敏度为72%~82%。
核心结论
- 作者认为,可对≥65岁社区居住的A/B期心衰人群使用经胸超声心动图筛查,以识别症状性心衰风险增加、可接受预防治疗者。
- 年轻个体中识别症状性心衰风险的最佳策略尚需进一步研究确定。
研究设计与样本
- 综述性文章,围绕无创心脏影像对临床前A/B期受试者症状性心衰进展的预测价值进行论述,未报告系统检索范围与纳入文献数量。
诊断标准与关键数值
- 收缩、舒张及结构左心室参数各自预测症状性心衰,但无单一参数灵敏度足以筛查A/B期进展风险人群。
- 经胸超声心动图在≥65岁A/B期人群中至少检出1项异常者占>50%。
- ≥65岁A/B期人群中经胸超声心动图至少1项异常预测后续症状性心衰的灵敏度为72%~82%。
临床应用与阅片要点
- 经胸超声心动图相比其他影像方式可同时测量收缩、舒张及结构左心室参数。
- 作者认为,对≥65岁社区居住的A/B期心衰人群可用经胸超声心动图识别症状性心衰风险增加者并给予预防治疗。
局限性
- 无单一参数具有足够灵敏度用于筛查识别A/B期心衰中疾病进展风险增加者。
- 年轻个体中识别症状性心衰风险的最佳策略尚需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Heart failure (HF) continues to grow as a cause of morbidity and mortality in our community and presents a significant public health problem, predominantly in individuals ≥65 years of age. Early intervention in asymptomatic HF subjects (Stage A/B) at risk of progression to symptomatic HF (Stage C/D) may provide an opportunity to halt this epidemic. The ability of cardiac imaging to assess cardiac structure and function permits early identification of those at increased risk of developing symptomatic HF. Systolic, diastolic, and structural left ventricular parameters each predict symptomatic HF, but no single parameter has sufficient sensitivity for screening to identify individuals with Stage A/B HF who are at increased risk of disease progression. Transthoracic echocardiography (TTE) has the advantage over other imaging modalities in being able to measure systolic, diastolic, and structural left ventricular parameters, and it identified at least 1 abnormal parameter in >50% of individuals with Stage A/B HF ≥65 years of age. Moreover, identification of at least 1 abnormality according to TTE in individuals with Stage A/B HF ≥65 years of age had 72% to 82% sensitivity for detection of those who subsequently developed symptomatic HF. Therefore, a case can be made for cardiac imaging by using TTE for community-dwelling populations with Stage A/B HF ≥65 years of age to identify those with increased risk of symptomatic HF who can be offered preventative therapies. Further studies are required to determine the best strategy for identifying the risk of symptomatic HF in younger individuals.
引用
- Gong FF, Campbell DJ, Prior DL, et al. Noninvasive Cardiac Imaging and the Prediction of Heart Failure Progression in Preclinical Stage A/B Subjects. JACC Cardiovasc Imaging. 2017. PMID: 29216977. doi:10.1016/j.jcmg.2017.11.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。